Nature Medicine
7, 283 - 285 (2001)
doi:10.1038/85414
Gazing into a crystal ball−cancer therapy in the post-genomic eraMark J. Ratain1, 3
& Mary V. Relling2, 31
University of Chicago, Chicago, Illinois, USA
2
St. Jude Children's Research Hospital and University of Tennessee, Memphis, Tennessee, USA
3
Pharmacogenetics of Anticancer Agents Research Group, Chicago, Illinois, USA
mratain@medicine.bsd.uchicago.edu
The sequencing of the human genome is likely to speed the discovery of factors involved in cancer pathogenesis and lead to an age of individually tailored anti-cancer drugs. But does the ability to obtain an abundance of genetic information mean that we necessarily know how to use it?
|
